What is the initial treatment protocol and monitoring sch...

Thank you for reaching out regarding this 9-year-old spayed female Beagle with confirmed pituitary-dependent hyperadrenocorticism (PDH). This is a common presentation, and a structured approach to treatment and monitoring is crucial for successful management.

Our primary goal with treating PDH is to improve the patient's quality of life by alleviating the clinical signs associated with cortisol excess – specifically the polyuria, polydipsia, and pendulous abdomen you've noted. We aim for clinical improvement rather than necessarily normalizing cortisol levels, as over-suppression can lead to iatrogenic hypoadrenocorticism.

Here is my initial treatment protocol and monitoring schedule:

Initial Treatment Protocol: Trilostane

Drug of Choice: Trilostane (Vetoryl®). This is the gold standard for managing PDH in dogs. It's an adrenal steroid synthesis inhibitor that reversibly inhibits 3-beta hydroxysteroid dehydrogenase, reducing the production of cortisol and other adrenal steroids.

Initial Dosing:

* I recommend starting at the lower end of the therapeutic range, typically 1-2 mg/kg orally BID (every 12 hours). Given her age and the potential for underlying comorbidities, a conservative start is prudent. For example, if she weighs 10 kg, a starting dose might be 10 mg PO BID.
* Administration: Trilostane should always be administered with food. This significantly improves its absorption and bioavailability.

Owner Education: Counsel the owner on expected changes. They should monitor for:

* Decreased water intake and urination frequency.
* Improved appetite (less ravenous, but not anorexic).
* Increased activity level.
* Reduction in the pendulous abdomen (over weeks to months).
* Warning signs: Lethargy, vomiting, diarrhea, anorexia, weakness – these could indicate over-suppression (iatrogenic hypoadrenocorticism) and warrant immediate veterinary attention.

Monitoring Schedule

Monitoring trilostane therapy relies on a combination of clinical signs, serum biochemistry (electrolytes, renal values), and post-ACTH stimulation tests.

Baseline (Pre-Trilostane):

* Ensure recent CBC, Chemistry panel (including electrolytes: Na, K, Cl), and Urinalysis are available. This establishes a baseline for renal function and electrolyte balance before starting medication.

First Recheck (Approximately 10-14 days after starting Trilostane):

* Timing of ACTH Stim Test: This is critical. The ACTH stimulation test should be performed 4-6 hours after the morning dose of Trilostane. This timing corresponds to the peak plasma concentration of trilostane and its active metabolites, providing the most accurate assessment of adrenal suppression at its maximum effect.
* Diagnostics:
* ACTH Stimulation Test: Collect a baseline cortisol, administer synthetic ACTH (cosyntropin) at 5 µg/kg IV or IM (max 250 µg per dog), and collect a post-ACTH cortisol sample 1 hour later.
* Chemistry Panel: Pay close attention to electrolytes (Na, K) and renal values (BUN, Creatinine).
* Interpretation and Dose Adjustment:
* Clinical Signs: Are the PU/PD and polyphagia improving? This is paramount.
* Post-ACTH Cortisol Target: Our target range for the post-ACTH cortisol is typically 1.5-5.0 µg/dL (40-140 nmol/L). However, clinical signs weigh heavily in decision-making.
* Dose Adjustment Guidelines:
Post-ACTH Cortisol < 1.0 µg/dL (28 nmol/L) AND clinical signs of hypoadrenocorticism: Discontinue trilostane for 3-7 days, then re-evaluate. Once clinical signs resolve, restart at a lower dose* (e.g., 25-50% reduction).
* Post-ACTH Cortisol < 1.0 µg/dL (28 nmol/L) BUT NO clinical signs of hypoadrenocorticism: Reduce the dose by 25-50%.
* Post-ACTH Cortisol 1.5-5.0 µg/dL (40-140 nmol/L) AND clinical signs are well-controlled: Continue current dose.
Post-ACTH Cortisol > 5.0 µg/dL (140 nmol/L) AND clinical signs are not* well-controlled: Increase the dose by 25-50%.
* Electrolyte Changes: If hyperkalemia or hyponatremia is present (suggesting mineralocorticoid deficiency), this is a strong indication to reduce or temporarily discontinue trilostane.

Second Recheck (Approximately 4 weeks after starting Trilostane, or 2 weeks after any dose adjustment):

* Repeat the ACTH stimulation test (4-6 hours post-pill) and Chemistry panel (with electrolytes).
* Adjust dose based on the same principles as above.

Maintenance Monitoring (Once stable):

* Once the patient's clinical signs are well-controlled and the post-ACTH cortisol is consistently in the target range, rechecks can be extended to every 3-6 months.
* Always perform an ACTH stim test (4-6 hours post-pill) and chemistry panel with electrolytes at these rechecks.
* Advise owners to contact you immediately if clinical signs of hyperadrenocorticism recur or if any signs of trilostane overdose develop.

Important Considerations:

* Consistency: Trilostane should be given consistently with food at the same time each day (BID).
* Cost: Trilostane can be expensive. Discuss the financial commitment with the owner.
* Iatrogenic Hypoadrenocorticism: This is the most serious potential side effect. Always advise owners about the signs (lethargy, vomiting, diarrhea, anorexia) and the need for immediate veterinary attention if they occur.
* Quality of Life: Remember, the primary goal is to improve the dog's quality of life. If a dog is clinically well, even if the post-ACTH cortisol is slightly outside the "ideal" range, we may not need to aggressively adjust the dose.

High confidence in this initial protocol. Please let me know if you have any further questions or if the initial monitoring reveals unexpected findings.